Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is strategically positioned for growth with their innovative product line for Afib and LAA management, along with investment in differentiation and strong clinical development. The company has shown promising sales growth and expects further success with new product launches in Europe. While there are potential risks, AtriCure is confident in their outlook and has raised their revenue, EBITDA, and EPS estimates for the future.

Bears say

AtriCure is a medical device company that specializes in surgical treatments and therapies for atrial fibrillation and left atrial appendage management. While the company has strong potential for growth, increased competition and reimbursement pressure in key international markets may negatively impact its financials in the long run. The company's EV/sales multiple of 3.0x is below its peers, but this could be attributed to its lower revenue growth compared to its competitors.

AtriCure (ATRC) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 6 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.